BLISS GVS PHARMA Financial Statement Analysis
|
||
|
The Revenues of BLISS GVS PHARMA have increased by 0.55% YoY .
The Earnings Per Share (EPS) of BLISS GVS PHARMA has increased by 368.97 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BLISS GVS PHARMA Last 5 Annual Financial Results
[BOM: 506197|NSE : BLISSGVS]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹752 Cr | ₹747 Cr | ₹577 Cr | ₹689 Cr | ₹899 Cr |
| Expenses | ₹634 Cr | ₹629 Cr | ₹471 Cr | ₹566 Cr | ₹741 Cr |
| Operating Profit (Excl OI) | ₹117 Cr | ₹118 Cr | ₹107 Cr | ₹123 Cr | ₹158 Cr |
| Other Income | ₹18 Cr | ₹31 Cr | ₹22 Cr | ₹39 Cr | ₹38 Cr |
| Interest | ₹10 Cr | ₹4.74 Cr | ₹7.24 Cr | ₹7.57 Cr | ₹4.42 Cr |
| Depreciation | ₹19 Cr | ₹17 Cr | ₹17 Cr | ₹13 Cr | ₹8.94 Cr |
| Profit Before Tax | ₹106 Cr | ₹54 Cr | ₹104 Cr | ₹129 Cr | ₹182 Cr |
| Profit After Tax | ₹77 Cr | ₹23 Cr | ₹74 Cr | ₹95 Cr | ₹127 Cr |
| Consolidated Net Profit | ₹71 Cr | ₹15 Cr | ₹68 Cr | ₹97 Cr | ₹124 Cr |
| Earnings Per Share (Rs) | ₹6.80 | ₹1.45 | ₹6.64 | ₹9.43 | ₹11.99 |
| PAT Margin (%) | 10.21 | 3.09 | 12.82 | 13.82 | 14.10 |
| ROE(%) | 9.11 | 2.88 | 9.64 | 13.79 | 21.43 |
| ROCE(%) | 12.22 | 6.37 | 12.49 | 17.02 | 26.58 |
| Total Debt/Equity(x) | 0.11 | 0.13 | 0.15 | 0.16 | 0.16 |
Key Financials |
||
| Market Cap | : | ₹ 1,193.6 Cr |
| Revenue (TTM) | : | ₹ 756.9 Cr |
| Net Profit(TTM) | : | ₹ 90.0 Cr |
| EPS (TTM) | : | ₹ 8.6 |
| P/E (TTM) | : | 13.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BLISS GVS PHARMA | 5.1% | -16.2% | 54.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
BLISS GVS PHARMA Revenues
[BOM: 506197|NSE : BLISSGVS]
| Y-o-Y | 0.55 % |
| 5 Yr CAGR | -4.37 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹752 Cr | 0.55 | |
| Mar2022 | ₹747 Cr | 29.50 | |
| Mar2021 | ₹577 Cr | -16.26 | |
| Mar2020 | ₹689 Cr | -23.29 | |
| Mar2019 | ₹899 Cr | - | |
BLISS GVS PHARMA Operating Profit
[BOM: 506197|NSE : BLISSGVS]
| Y-o-Y | -0.86 % |
| 5 Yr CAGR | -7.12 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹117 Cr | -0.86 | |
| Mar2022 | ₹118 Cr | 10.97 | |
| Mar2021 | ₹107 Cr | -13.52 | |
| Mar2020 | ₹123 Cr | -21.77 | |
| Mar2019 | ₹158 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.39 % |
| 5 Yr CAGR | -2.87 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 15.61% | -1.39 | |
| Mar2022 | 15.83% | -14.34 | |
| Mar2021 | 18.48% | 3.30 | |
| Mar2020 | 17.89% | 2.00 | |
| Mar2019 | 17.54% | - | |
BLISS GVS PHARMA Profit After Tax
[BOM: 506197|NSE : BLISSGVS]
| Y-o-Y | 371.14 % |
| 5 Yr CAGR | -13.01 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹71 Cr | 371.14 | |
| Mar2022 | ₹15 Cr | -78.04 | |
| Mar2021 | ₹68 Cr | -29.58 | |
| Mar2020 | ₹97 Cr | -21.38 | |
| Mar2019 | ₹124 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 230.42 % |
| 5 Yr CAGR | -7.75 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 10.21 % | 230.42 | |
| Mar2022 | 3.09 % | -75.90 | |
| Mar2021 | 12.82 % | -7.24 | |
| Mar2020 | 13.82 % | -1.99 | |
| Mar2019 | 14.1 % | - | |
BLISS GVS PHARMA Earnings Per Share (EPS)
[BOM: 506197|NSE : BLISSGVS]
| Y-o-Y | 368.97 % |
| 5 Yr CAGR | -13.22 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹6.80 | 368.97 | |
| Mar2022 | ₹1.45 | -78.16 | |
| Mar2021 | ₹6.64 | -29.59 | |
| Mar2020 | ₹9.43 | -21.35 | |
| Mar2019 | ₹12 | - | |
BLISS GVS PHARMA Return on Capital Employed (ROCE)
[BOM: 506197|NSE : BLISSGVS]
| Y-o-Y | 91.84 % |
| 5 Yr CAGR | -17.66 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 12.22% | 91.84 | |
| Mar2022 | 6.37% | -49.00 | |
| Mar2021 | 12.49% | -26.62 | |
| Mar2020 | 17.02% | -35.97 | |
| Mar2019 | 26.58% | - | |
BLISS GVS PHARMA Share Price vs Sensex
| Current Share Price | : | ₹114.0 |
| Current MarketCap | : | ₹ 1,193.6 Cr |
| Updated EOD on | : | Apr 23,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BLISS GVS PHARMA | 5.1% |
-16.2% |
54.7% |
| SENSEX | 0.5% |
1.4% |
23.5% |
BLISS GVS PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 2.9% | 10.7% | 64.6% |
| S&P BSE MIDSMALLCAP | 1.9% | 8.5% | 63.5% |
| S&P BSE ALLCAP | 1% | 4.4% | 39.7% |
| S&P BSE HEALTHCARE | -0.9% | 1.1% | 50.9% |
No NSE index found
You may also like the below Video Courses
FAQ about BLISS GVS PHARMA Financials
How the annual revenues of BLISS GVS PHARMA have changed ?
The Revenues of BLISS GVS PHARMA have increased by 0.55% YoY .
How the Earnings per Share (EPS) of BLISS GVS PHARMA have changed?
The Earnings Per Share (EPS) of BLISS GVS PHARMA has increased by 368.97 % YoY .
Check out Intrinsic Value of Peers of BLISS GVS PHARMA
Compare Stock Analytics of Peers of BLISS GVS PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
